Advertisement AliX and SOSHO to Sign Agreement for Protein Structure Determination of Intractable Targets - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

NovAliX

Small Molecule Drug Discovery

More info about NovAliX

AliX and SOSHO to Sign Agreement for Protein Structure Determination of Intractable Targets

AliX, a NovAliX company with
capabilities in structural biology and SOSHO, an Osaka university spin-off with expertise in
crystallogenesis have announced today that they have entered into an exclusive agreement
to supply biopharmaceuticals companies with protein structure determination solutions for
difficult targets.

Within the frame of the collaboration, AliX will provide SOSHO with its protein engineering
expertise and SOSHO will apply its breakthrough crystallisation technology. SOSHO is using
femto-second laser irradiation of protein solution to induce crystal nucleation and to promote
crystal growth. Laser irradiation allows exploring novel crystallisation conditions leading to
higher quality crystals with better diffraction properties.

Joining forces, AliX and SOSHO will offer enhanced protein structure determination services
to biopharmaceuticals companies. In addition, AliX and SOSHO have already started a
research collaboration to determine crystal structures of intractable targets relevant to
therapeutic research. According to Dr Jean-Paul Renaud, CSO of AliX, and Pr Tsuyoshi Inoue,
CSO of SOSHO, combining the expertise of both companies will provide a unique opportunity
to solve difficult problems, including membrane protein crystallisation.

Quick Contact